CR20240347A - Compuestos de benzopirimidina y uso de estos - Google Patents

Compuestos de benzopirimidina y uso de estos

Info

Publication number
CR20240347A
CR20240347A CR20240347A CR20240347A CR20240347A CR 20240347 A CR20240347 A CR 20240347A CR 20240347 A CR20240347 A CR 20240347A CR 20240347 A CR20240347 A CR 20240347A CR 20240347 A CR20240347 A CR 20240347A
Authority
CR
Costa Rica
Prior art keywords
compounds
benzopyrimidine
disclosed
series
formula
Prior art date
Application number
CR20240347A
Other languages
English (en)
Inventor
Kaijun Geng
Yang Zhang
Shuhui Chen
Yangyang Xu
Jian Li
Jikui Sun
Wentao Wu
Original Assignee
Usynova Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2022/075732 external-priority patent/WO2022171147A1/zh
Application filed by Usynova Pharmaceuticals Ltd filed Critical Usynova Pharmaceuticals Ltd
Publication of CR20240347A publication Critical patent/CR20240347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan una serie de compuestos de benzopirimidina y un uso de estos, y específicamente se divulgan compuestos representados mediante la fórmula (II) y sales farmacéuticamente aceptables de estos
CR20240347A 2022-01-21 2023-01-19 Compuestos de benzopirimidina y uso de estos CR20240347A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202210072243 2022-01-21
CN202210113080 2022-01-29
PCT/CN2022/075732 WO2022171147A1 (zh) 2021-02-09 2022-02-09 嘧啶并芳香环类化合物
CN202210239568 2022-03-11
CN202210693538 2022-06-17
CN202210837790 2022-07-15
CN202210989455 2022-08-17
PCT/CN2023/073182 WO2023138662A1 (zh) 2022-01-21 2023-01-19 苯并嘧啶类化合物及其应用

Publications (1)

Publication Number Publication Date
CR20240347A true CR20240347A (es) 2025-02-17

Family

ID=87347868

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240347A CR20240347A (es) 2022-01-21 2023-01-19 Compuestos de benzopirimidina y uso de estos

Country Status (15)

Country Link
US (2) US12410196B2 (es)
EP (1) EP4371991A4 (es)
JP (1) JP7629580B1 (es)
KR (1) KR20240136407A (es)
CN (1) CN118355019B (es)
AU (1) AU2023210005B2 (es)
CL (1) CL2024002183A1 (es)
CO (1) CO2024011210A2 (es)
CR (1) CR20240347A (es)
DO (1) DOP2024000134A (es)
IL (1) IL314296B2 (es)
MX (1) MX2024008849A (es)
PE (1) PE20241937A1 (es)
WO (1) WO2023138662A1 (es)
ZA (1) ZA202406389B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523101A (ja) * 2022-07-12 2025-07-17 メッドシャイン ディスカバリー インコーポレイテッド ピペラジン架橋置換複素環ピリミジン系化合物
KR20250048579A (ko) * 2022-08-16 2025-04-09 브리스톨-마이어스 스큅 컴퍼니 Kras 억제제
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025002302A1 (zh) 2023-06-28 2025-01-02 广东东阳光药业股份有限公司 嘧啶并吡啶化合物、其药物组合物及其用途
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
US11453667B2 (en) * 2018-01-19 2022-09-27 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022002102A1 (en) * 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
EP4182313A4 (en) 2020-07-16 2024-10-09 Mirati Therapeutics, Inc. KRAS-G12D INHIBITORS
EP4192585A4 (en) 2020-08-04 2024-08-21 Mirati Therapeutics, Inc. Kras g12d inhibitors
US20230081426A1 (en) * 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
US20230365563A1 (en) * 2020-09-30 2023-11-16 Shanghai Pharmaceuticals Holding Co., Ltd. Quinazoline compound and application thereof
WO2022098625A1 (en) 2020-11-03 2022-05-12 Mirati Therapeutics, Inc. Kras g12d inhibitors
US20240059710A1 (en) * 2020-11-20 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. KRAS G12D Inhibitors
US20240140957A1 (en) * 2021-01-08 2024-05-02 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
BR112023015976A2 (pt) * 2021-02-09 2023-12-12 Medshine Discovery Inc Compostos de anel aromático de pirimidina
AU2022219651A1 (en) 2021-02-15 2023-09-07 Astellas Pharma Inc. 4-aminoquinazoline compound
AU2022224511A1 (en) 2021-02-16 2023-08-10 Lawrence Livermore National Security, Llc Compositions and methods for inhibition of ras
WO2022187528A1 (en) 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline amine derivatives as kras inhibitors
IL305568A (en) * 2021-03-12 2023-10-01 Bristol Myers Squibb Co KRAS G12D inhibitors
TWI810803B (zh) 2021-03-15 2023-08-01 大陸商藥雅科技（上海）有限公司 突變蛋白抑制劑的製備及其應用
WO2022221739A1 (en) * 2021-04-16 2022-10-20 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12d mutant
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
CN115385938A (zh) * 2021-05-25 2022-11-25 江苏恒瑞医药股份有限公司 苯并嘧啶类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR20240136407A (ko) 2024-09-13
CA3247773A1 (en) 2025-04-25
US20240383924A1 (en) 2024-11-21
WO2023138662A9 (zh) 2024-05-16
CN118355019A (zh) 2024-07-16
JP2025505112A (ja) 2025-02-21
DOP2024000134A (es) 2024-12-15
EP4371991A4 (en) 2025-02-26
IL314296A (en) 2024-09-01
EP4371991A1 (en) 2024-05-22
IL314296B1 (en) 2025-07-01
MX2024008849A (es) 2024-07-25
AU2023210005B2 (en) 2024-12-19
ZA202406389B (en) 2025-06-25
CN118355019B (zh) 2025-02-14
CL2024002183A1 (es) 2024-10-18
PE20241937A1 (es) 2024-09-24
CO2024011210A2 (es) 2024-12-09
WO2023138662A1 (zh) 2023-07-27
AU2023210005A1 (en) 2024-09-05
JP7629580B1 (ja) 2025-02-13
US12410196B2 (en) 2025-09-09
IL314296B2 (en) 2025-11-01
US20250270233A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
ZA202406389B (en) Benzopyrimidine compounds and use thereof
MX2024015714A (es) Compuesto de pirimidopirano sustituido heterocíclico y uso de este
PH12022552395A1 (en) Pyrimidoheterocyclic compounds and application thereof
MX2025003665A (es) Derivados macrociclicos y las aplicaciones de estos
MX2023009278A (es) Compuestos ciclicos aromaticos pirimidina.
CR20220354A (es) Inhibidores de egfr
MX2025011447A (es) Inhibidores de kras
ZA202401567B (en) Ring-modified proline short peptide compound and use thereof
PH12021552805A1 (en) Cdk inhibitors
ZA202500635B (en) Piperazine bridge-substituted heterocyclic pyrimidine compound
CL2024000067A1 (es) Compuestos antivirales
ZA202308002B (en) Pyrimidopyran compound
WO2021079196A3 (en) Mettl3 modulators
MY207276A (en) Modulators of trex1
MX2024001352A (es) Inhibidor novedoso de la poli(adp-ribosa) polimerasa y uso del mismo.
MX2025013480A (es) Compuestos heterocíclicos que contienen nitrógeno y uso de los mismos
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
MX2025001749A (es) Compuesto como inhibidor del canal de sodio dependiente del voltaje
MX2024014185A (es) Conjugado de ligando-fármaco y usos de estos
MX2024012267A (es) Inhibidores de egfr
PH12023553004A1 (en) Modulators of trex1
CR20240352A (es) Compuestos de uracilo sustituidos por n3 como inhibidores de trpa1
MX2025007548A (es) Pirroloquinazolinonas espirociclicas sustituidas y piperidinoquinazolinonas espirociclicas sustituidas
WO2021087086A8 (en) Condensed pyridazine or pyrimidine as btk inhibitors
WO2022057836A8 (zh) 苯并脲环衍生物及其制备方法和应用